ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference Read more about ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference
ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference Read more about ZyVersa Therapeutics to Participate in a Fireside Chat at Roth Annual Conference
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury Read more about ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury
ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4) Read more about ZyVersa Therapeutics Reports Inducement Grant to Newly Appointed Chief Medical Officer Under Nasdaq Listing Rule 5635(c)(4)
ZyVersa Therapeutics to Present at BIO CEO & Investor Conference Read more about ZyVersa Therapeutics to Present at BIO CEO & Investor Conference
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event Read more about ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Present at the Virtual Investor 2023 Companies to Watch Event
ZyVersa Therapeutics Appoints Three New Board Members Read more about ZyVersa Therapeutics Appoints Three New Board Members
ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200 Read more about ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 41st Annual J.P. Morgan Healthcare Conference Read more about ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 41st Annual J.P. Morgan Healthcare Conference
ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA") Read more about ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker "ZVSA")
